Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II Study Evaluating Denosumab (XGEVA®) in Combination with Nivolumab (OPDIVO®) As Second-line Therapy for Patients with Stage IV Non-small-cell Lung Cancer (squamous and Non-squamous) with Bone Metastases: DENIVOS STUDY

NCT03669523 is registered in ClinicalTrials.gov with Centre Hospitalier Annecy Genevois as lead sponsor.

NCT NCT03669523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03669523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II Study Evaluating Denosumab (XGEVA®) in Combination with Nivolumab (OPDIVO®) As Second-line Therapy for Patients with Stage IV Non-small-cell Lung Cancer (squamous and Non-squamous) with Bone Metastases: DENIVOS STUDY
Lead sponsor
Centre Hospitalier Annecy Genevois
Phase
Phase 2
Overall status
Completed
Start date
November 6, 2018
Completion date
October 19, 2023
Enrollment
82 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases, carcinoma, non-small-cell lung